These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2191470)

  • 1. [Methods for studying the hepatic metabolism of drugs in man].
    Geneve J; Bergmann JF; Caulin C; Segrestaa JM
    Therapie; 1990; 45(2):91-7. PubMed ID: 2191470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetic control of drug oxidation in the liver.
    Dayer P; Balant L; Fabre J
    Int J Clin Pharmacol Res; 1983; 3(6):421-5. PubMed ID: 6147316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Genetic polymorphism of the hepatic metabolism of drugs].
    Larrey D; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1985; 9(6-7):522-31. PubMed ID: 3926587
    [No Abstract]   [Full Text] [Related]  

  • 4. [Stability and/or variability of the expression of genetic polymorphism of hydroxylation and acetylation in patients with various pathologies and under various treatments].
    Bechtel P; Joanne C; Bechtel Y; Grandmottet M; Jounet JM
    Ann Biol Clin (Paris); 1986; 44(4):361-7. PubMed ID: 3538951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro tests of hepatic oxidation in man, predictive of drug interactions].
    Dayer P; Leemann T; Striberni R; Meyer P
    Schweiz Med Wochenschr; 1987 Dec; 117(49):1971-3. PubMed ID: 3423780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of circadian rhythms on the kinetics of drugs in humans.
    Baraldo M
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):175-92. PubMed ID: 18248311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive methods for the assessment of hepatic drug disposition.
    Bircher J
    Int J Clin Pharmacol Res; 1983; 3(6):415-9. PubMed ID: 6432711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatic clearance of drugs. Physiological and pharmacokinetic considerations].
    Pellegrin P; Lesne M
    J Pharmacol; 1983; 14(2):107-39. PubMed ID: 6865443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of model traumatic injury on hepatic drug metabolism in the rat. III. Differential responses of cytochrome P-450 subpopulations.
    Griffeth LK; Rosen GM; Rauckman EJ
    Drug Metab Dispos; 1984; 12(5):588-95. PubMed ID: 6149909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Individual variations in the oxidative metabolism of drugs. Significance of monogenic polymorphism].
    Brøsen K
    Ugeskr Laeger; 1984 Mar; 146(13):955-9. PubMed ID: 6719598
    [No Abstract]   [Full Text] [Related]  

  • 11. First-principle, structure-based prediction of hepatic metabolic clearance values in human.
    Li H; Sun J; Sui X; Liu J; Yan Z; Liu X; Sun Y; He Z
    Eur J Med Chem; 2009 Apr; 44(4):1600-6. PubMed ID: 18768239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Fluosol-DA hemodilution on the kinetics of hepatically eliminated drugs.
    Shrewsbury RP
    Res Commun Chem Pathol Pharmacol; 1987 Mar; 55(3):375-96. PubMed ID: 3575876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Oct; 59(10):1427-31. PubMed ID: 17910819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
    Faber MS; Jetter A; Fuhr U
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Foreign substances as indicators of liver function].
    Preisig R
    Schweiz Med Wochenschr Suppl; 1985; 19():36-42. PubMed ID: 3864235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Liver metabolism of indocyanine green and aminopyrine in liver cirrhosis: relations with functioning liver cell mass].
    Bolognesi M; Merkel C; Angeli P; Caregaro L; Gatta A
    Minerva Med; 1988 Dec; 79(12):1035-41. PubMed ID: 3211355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.